WAVE Life Sciences (NASDAQ:WVE) Stock Price Up 5.9% – Time to Buy?

WAVE Life Sciences Ltd. (NASDAQ:WVE) was up 5.9% during mid-day trading on Friday . The company traded as high as $6.62 and last traded at $6.5650. Approximately 5,741,936 shares traded hands during trading, an increase of 37% from the average daily volume of 4,196,267 shares. The stock had previously closed at $6.20.

WAVE Life Sciences News Roundup

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Company press release: WAVE reported a single 240 mg dose produced placebo‑adjusted reductions of ~14% visceral fat, 5% total fat, increases in lean mass and waist circumference improvement at 6 months — data the company framed as clinically meaningful. Wave press release
• Positive Sentiment: Some analysts remain constructive: Truist upgraded WVE to “strong‑buy” and Mizuho published a bullish forecast, signaling at least a subset of Wall Street sees longer‑term upside despite the selloff. Zacks / Truist note Mizuho note
• Neutral Sentiment: Broker commentary is mixed: some outlets present the INLIGHT data as “positive” on body composition (visceral fat), while others focus on the modest weight‑loss metric — the clinical readout is therefore being interpreted both ways by investors and clinicians. Seeking Alpha slideshow
• Negative Sentiment: Market reaction: Shares plunged sharply after investors focused on the small (~0.9%) placebo‑adjusted weight loss and a lack of clear dose improvement at higher dose — headlines and flows drove a large intraday selloff. Reuters
• Negative Sentiment: Analyst adjustments: Wells Fargo cut its price target from $27 to $13 (still “overweight”) and Bank of America cut from $38 to $21 (still “buy”). Those sizable PT reductions lower the near‑term upside consensus and reflect reduced investor confidence. Benzinga (Wells Fargo / BofA notes)
• Negative Sentiment: Legal/claims risk: A law firm (Johnson Fistel) has announced an investigation into potential investor claims tied to WAVE’s disclosures, adding regulatory/legal uncertainty and potential headline risk. GlobeNewswire / Johnson Fistel
• Negative Sentiment: Heavy volume and volatility: Trading volume spiked well above average as the stock traded near 12‑month lows, increasing downside risk and pressuring short‑term technical support. Multiple outlets highlighted a >50% selloff. MSN

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Mizuho raised their price target on shares of WAVE Life Sciences from $22.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Wednesday, January 21st. Citigroup raised their price objective on shares of WAVE Life Sciences from $16.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Royal Bank Of Canada raised shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $9.00 to $27.00 in a research report on Monday, December 8th. Finally, Wells Fargo & Company cut their target price on shares of WAVE Life Sciences from $27.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.38.

WAVE Life Sciences Stock Up 5.9%

The stock has a market cap of $1.24 billion, a P/E ratio of -5.39 and a beta of -1.77. The firm’s 50 day simple moving average is $13.08 and its two-hundred day simple moving average is $11.20.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%.The business had revenue of $17.25 million during the quarter, compared to the consensus estimate of $15.68 million. As a group, equities analysts predict that WAVE Life Sciences Ltd. will post -1.14 EPS for the current year.

Insider Buying and Selling

In related news, CFO Kyle Moran sold 3,588 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $48,258.60. Following the completion of the transaction, the chief financial officer directly owned 134,385 shares in the company, valued at $1,807,478.25. This represents a 2.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Chandra Vargeese sold 3,228 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $43,416.60. Following the completion of the sale, the insider directly owned 408,246 shares in the company, valued at $5,490,908.70. This represents a 0.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 61,748 shares of company stock valued at $907,809 over the last three months. 23.98% of the stock is owned by company insiders.

Institutional Trading of WAVE Life Sciences

A number of large investors have recently modified their holdings of WVE. Hsbc Holdings PLC boosted its stake in WAVE Life Sciences by 52.1% during the 4th quarter. Hsbc Holdings PLC now owns 16,990 shares of the company’s stock valued at $291,000 after purchasing an additional 5,823 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of WAVE Life Sciences during the fourth quarter valued at approximately $176,000. Virtu Financial LLC acquired a new position in shares of WAVE Life Sciences during the fourth quarter worth approximately $457,000. Invesco Ltd. grew its holdings in WAVE Life Sciences by 27.5% in the 4th quarter. Invesco Ltd. now owns 179,932 shares of the company’s stock worth $3,059,000 after buying an additional 38,806 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in WAVE Life Sciences during the 4th quarter valued at $12,278,000. Institutional investors and hedge funds own 89.73% of the company’s stock.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.